Market News & Trends
Codiak BioSciences & CEPI Partner to Develop Broadly Protective Betacoronavirus Vaccine
CEPI, the Coalition for Epidemic Preparedness Innovations, and Codiak BioSciences recently announced the latest funding award under CEPI’s US $200 million program to advance the development of vaccines that provide broad protection against….
Fastox to Present its Long-Lasting Botulinum Toxin LAST Technology
Swiss biotech Fastox Pharma will present for the first time its groundbreaking long-lasting botulinum toxin LAST technology at the leading conference on neurotoxins from July…
Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial
Fulcrum Therapeutics, Inc. recently announced the first patient has been dosed in REACH, a Phase 3 clinical trial designed to evaluate the safety and efficacy…
DFE Pharma Expands its Inhalation Portfolio With New Launch
DFE Pharma recently announced the expansion of its Dry Powder Inhalation (DPI) portfolio with the launch of Lactohale 400. The addition of Lactohale 400 further enhances the completeness of DFE Pharma’s portfolio of inhalation-grade lactose…..
Sanara MedTech Inc. Announces Closing of Scendia Biologics, LLC Acquisition
Sanara MedTech Inc. recently announced it closed the acquisition of Scendia Biologics, LLC on July 1, 2022. Prior to this acquisition, Scendia was a sub-distributor…
Evonik Launches Non-Animal-Derived Collagen Platform at Commercial Scale for Medical Device Applications
Evonik’s recombinant, non-animal-derived collagen platform is now available at commercial scale. Vecollan is a highly pure and soluble collagen that is produced via fermentation. It…
BriaCell Partners With Waisman Biomanufacturing to Manufacture & Supply Prostate Cancer Immunotherapy
BriaCell Therapeutics Corp. has recently entered a manufacturing service agreement with Waisman Biomanufacturing at the University of Wisconsin–Madison (Waisman), to manufacture Bria-Pros, BriaCell’s off-the-shelf personalized….
Chinook Therapeutics Receives Orphan Drug Designation for BION-1301 for Treatment of Primary IgA Nephropathy
Chinook Therapeutics, Inc. recently announced the European Commission has granted orphan drug designation for BION-1301 for the treatment of primary IgA nephropathy (IgAN). The decision…
BD Unveils World's First Spectral Cell Sorter With High-Speed Imaging Technology That Sorts Cells Based on Visual Characteristics
BD (Becton, Dickinson and Company) recently announced it introduced new cell sorting technology at the International Society for Advancement of Cytometry (ISAC) CYTO 2022 conference…
Cara Therapeutics Announces Positive Topline Results From Phase 2 Trial of Oral Difelikefalin
Cara Therapeutics, Inc. recently announced positive topline results from its Phase 2 proof-of-concept clinical trial (KOMFORT) evaluating oral difelikefalin for the treatment of moderate-to-severe pruritus in….
Catalent Expands Primary Packaging Capabilities at its Clinical Supply Facility in Japan
Catalent recently announced it has expanded its primary packaging capabilities at its clinical supply facility in Shiga, Japan, through the installation of a high-speed blister…
BioCorRx Announces First Subject Dosed in Phase 1 Clinical Trial of Implantable Naltrexone Pellet
BioCorRx Inc. recently announced the first subject has been dosed in the Phase 1 clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the…
US Government to Support Expansion of Croda Lipid Systems Capability
Croda International Plc recently announced it has entered into a cooperative agreement with the US government in which the government will provide up to $75 million to expand the….
Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy
Neurona Therapeutics recently announced the first patient dosed in a Phase 1/2 clinical trial of its lead program, NRTX-1001, in a first-in-human epilepsy study…..
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease
AN2 Therapeutics, Inc. recently announced it has screened its first patient in its pivotal Phase 2/3 clinical trial evaluating once-daily, oral epetraborole for treatment-refractory Mycobacterium avium complex…..
Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor
Ventyx Biosciences, Inc. recently announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX2735, a…
SciSparc Successfully Completed Development of its Proprietary Drug Candidate for Upcoming Phase 2b Study in Tourette Syndrome
SciSparc Ltd. recently announced it has successfully completed the development of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase…
Ocuphire Granted New US Patent for Late-Stage Oral Drug Candidate
Ocuphire Pharma, Inc. recently announced the USPTO has issued a new patent extending expiry and broadening coverage of the company’s late-stage oral product candidate, APX3330.…
BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment
BriaCell Therapeutics Corp. recently announced a research collaboration agreement with Harvard Medical School in support of a project led by Joan S. Brugge, PhD, a faculty…
Norstella & Citeline Unite to Offer Life Sciences Clients a Full Suite of Commercial & Clinical Solutions
Norstella and Citeline (formerly Pharma Intelligence) have recently announced an agreement to merge the companies. By uniting Norstella, which is composed of four prominent pharmaceutical solutions providers….
